Research ExplorerPublicationsSafety and Effectiveness of Edoxaban in Atrial Fibrillation ...

Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program

Standard

Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program. / De Caterina, Raffaele; Kim, Young-Hoon; Koretsune, Yukihiro; Wang, Chun-Chieh; Yamashita, Takeshi; Chen, Cathy; Reimitz, Paul-Egbert; Unverdorben, Martin; Kirchhof, Paulus.

In: J CLIN MED, Vol. 10, No. 4, 573, 03.02.2021.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

De Caterina, R, Kim, Y-H, Koretsune, Y, Wang, C-C, Yamashita, T, Chen, C, Reimitz, P-E, Unverdorben, M & Kirchhof, P 2021, 'Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program', J CLIN MED, vol. 10, no. 4, 573. https://doi.org/10.3390/jcm10040573

APA

De Caterina, R., Kim, Y-H., Koretsune, Y., Wang, C-C., Yamashita, T., Chen, C., Reimitz, P-E., Unverdorben, M., & Kirchhof, P. (2021). Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program. J CLIN MED, 10(4), [573]. https://doi.org/10.3390/jcm10040573

Vancouver

De Caterina R, Kim Y-H, Koretsune Y, Wang C-C, Yamashita T, Chen C et al. Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program. J CLIN MED. 2021 Feb 3;10(4). 573. https://doi.org/10.3390/jcm10040573

Bibtex

@article{e1f4d1043b474c7d94e29021548fba9c,
title = "Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program",
abstract = "Non-vitamin K antagonist oral anticoagulants such as edoxaban are the standard of care for stroke prevention in patients with atrial fibrillation (AF). The Global Edoxaban Treatment in routiNe clinical prActice (ETNA)-AF program integrates prospective, observational, noninterventional regional studies from Europe, Japan, and other Asian countries, collecting data on patient characteristics and clinical outcomes in unselected patients treated with edoxaban for stroke prevention in AF. Overall, 26,823 patients completed a 1-year follow-up and were treated with edoxaban; either 60 or 30 mg once daily. The majority (82.6%) of patients received the recommended doses according to the local label. At baseline, the median (interquartile range) age was 75 (68, 80) years, the CHA2DS2-VASc score was 3.0 (2.0, 4.0), and the hypertension, abnormal renal and liver function, stroke, bleeding, labile international normalized ratio, elderly, drugs, or alcohol (HAS-BLED) score was 2.0 (2.0, 3.0). At one year, there were 273 (1.12%/year) major bleeding events, including 75 (0.31%/year) intracranial hemorrhages and 140 (0.57%/year) major gastrointestinal (GI) bleeds. There were 214 ischemic strokes (0.87%/year). Mortality was 3.03%/year (745 deaths), and cardiovascular mortality accounted for 40% of all deaths (1.22%/year, 299 cardiovascular deaths). In conclusion, stroke, intracranial hemorrhage, and other major bleeding events were low in patients with AF treated with edoxaban in routine care. Even on anticoagulation, cardiovascular death remained common.",
author = "{De Caterina}, Raffaele and Young-Hoon Kim and Yukihiro Koretsune and Chun-Chieh Wang and Takeshi Yamashita and Cathy Chen and Paul-Egbert Reimitz and Martin Unverdorben and Paulus Kirchhof",
year = "2021",
month = feb,
day = "3",
doi = "10.3390/jcm10040573",
language = "English",
volume = "10",
journal = "J CLIN MED",
issn = "2077-0383",
publisher = "MDPI AG",
number = "4",

}

RIS

TY - JOUR

T1 - Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program

AU - De Caterina, Raffaele

AU - Kim, Young-Hoon

AU - Koretsune, Yukihiro

AU - Wang, Chun-Chieh

AU - Yamashita, Takeshi

AU - Chen, Cathy

AU - Reimitz, Paul-Egbert

AU - Unverdorben, Martin

AU - Kirchhof, Paulus

PY - 2021/2/3

Y1 - 2021/2/3

N2 - Non-vitamin K antagonist oral anticoagulants such as edoxaban are the standard of care for stroke prevention in patients with atrial fibrillation (AF). The Global Edoxaban Treatment in routiNe clinical prActice (ETNA)-AF program integrates prospective, observational, noninterventional regional studies from Europe, Japan, and other Asian countries, collecting data on patient characteristics and clinical outcomes in unselected patients treated with edoxaban for stroke prevention in AF. Overall, 26,823 patients completed a 1-year follow-up and were treated with edoxaban; either 60 or 30 mg once daily. The majority (82.6%) of patients received the recommended doses according to the local label. At baseline, the median (interquartile range) age was 75 (68, 80) years, the CHA2DS2-VASc score was 3.0 (2.0, 4.0), and the hypertension, abnormal renal and liver function, stroke, bleeding, labile international normalized ratio, elderly, drugs, or alcohol (HAS-BLED) score was 2.0 (2.0, 3.0). At one year, there were 273 (1.12%/year) major bleeding events, including 75 (0.31%/year) intracranial hemorrhages and 140 (0.57%/year) major gastrointestinal (GI) bleeds. There were 214 ischemic strokes (0.87%/year). Mortality was 3.03%/year (745 deaths), and cardiovascular mortality accounted for 40% of all deaths (1.22%/year, 299 cardiovascular deaths). In conclusion, stroke, intracranial hemorrhage, and other major bleeding events were low in patients with AF treated with edoxaban in routine care. Even on anticoagulation, cardiovascular death remained common.

AB - Non-vitamin K antagonist oral anticoagulants such as edoxaban are the standard of care for stroke prevention in patients with atrial fibrillation (AF). The Global Edoxaban Treatment in routiNe clinical prActice (ETNA)-AF program integrates prospective, observational, noninterventional regional studies from Europe, Japan, and other Asian countries, collecting data on patient characteristics and clinical outcomes in unselected patients treated with edoxaban for stroke prevention in AF. Overall, 26,823 patients completed a 1-year follow-up and were treated with edoxaban; either 60 or 30 mg once daily. The majority (82.6%) of patients received the recommended doses according to the local label. At baseline, the median (interquartile range) age was 75 (68, 80) years, the CHA2DS2-VASc score was 3.0 (2.0, 4.0), and the hypertension, abnormal renal and liver function, stroke, bleeding, labile international normalized ratio, elderly, drugs, or alcohol (HAS-BLED) score was 2.0 (2.0, 3.0). At one year, there were 273 (1.12%/year) major bleeding events, including 75 (0.31%/year) intracranial hemorrhages and 140 (0.57%/year) major gastrointestinal (GI) bleeds. There were 214 ischemic strokes (0.87%/year). Mortality was 3.03%/year (745 deaths), and cardiovascular mortality accounted for 40% of all deaths (1.22%/year, 299 cardiovascular deaths). In conclusion, stroke, intracranial hemorrhage, and other major bleeding events were low in patients with AF treated with edoxaban in routine care. Even on anticoagulation, cardiovascular death remained common.

U2 - 10.3390/jcm10040573

DO - 10.3390/jcm10040573

M3 - SCORING: Journal article

C2 - 33546442

VL - 10

JO - J CLIN MED

JF - J CLIN MED

SN - 2077-0383

IS - 4

M1 - 573

ER -